Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

918 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade.
Johnson PJ, Berhane S, Kagebayashi C, Satomura S, Teng M, Reeves HL, O'Beirne J, Fox R, Skowronska A, Palmer D, Yeo W, Mo F, Lai P, Iñarrairaegui M, Chan SL, Sangro B, Miksad R, Tada T, Kumada T, Toyoda H. Johnson PJ, et al. Among authors: mo f. J Clin Oncol. 2015 Feb 20;33(6):550-8. doi: 10.1200/JCO.2014.57.9151. Epub 2014 Dec 15. J Clin Oncol. 2015. PMID: 25512453 Free PMC article.
An intensive surveillance program detected a high incidence of hepatocellular carcinoma among hepatitis B virus carriers with abnormal alpha-fetoprotein levels or abdominal ultrasonography results.
Mok TS, Yeo W, Yu S, Lai P, Chan HL, Chan AT, Lau JW, Wong H, Leung N, Hui EP, Sung J, Koh J, Mo F, Zee B, Johnson PJ. Mok TS, et al. Among authors: mo f. J Clin Oncol. 2005 Nov 1;23(31):8041-7. doi: 10.1200/JCO.2005.01.9927. J Clin Oncol. 2005. PMID: 16258102
Role of the GALAD and BALAD-2 Serologic Models in Diagnosis of Hepatocellular Carcinoma and Prediction of Survival in Patients.
Berhane S, Toyoda H, Tada T, Kumada T, Kagebayashi C, Satomura S, Schweitzer N, Vogel A, Manns MP, Benckert J, Berg T, Ebker M, Best J, Dechêne A, Gerken G, Schlaak JF, Weinmann A, Wörns MA, Galle P, Yeo W, Mo F, Chan SL, Reeves H, Cox T, Johnson P. Berhane S, et al. Among authors: mo f. Clin Gastroenterol Hepatol. 2016 Jun;14(6):875-886.e6. doi: 10.1016/j.cgh.2015.12.042. Epub 2016 Jan 13. Clin Gastroenterol Hepatol. 2016. PMID: 26775025
Long-term impact of liver function on curative therapy for hepatocellular carcinoma: application of the ALBI grade.
Toyoda H, Lai PB, O'Beirne J, Chong CC, Berhane S, Reeves H, Manas D, Fox RP, Yeo W, Mo F, Chan AW, Tada T, Iñarrairaegui M, Vogel A, Schweitzer N, Chan SL, Sangro B, Kumada T, Johnson PJ. Toyoda H, et al. Among authors: mo f. Br J Cancer. 2016 Mar 29;114(7):744-50. doi: 10.1038/bjc.2016.33. Br J Cancer. 2016. PMID: 27022825 Free PMC article.
Transarterial chemo-embolisation of hepatocellular carcinoma: impact of liver function and vascular invasion.
Waked I, Berhane S, Toyoda H, Chan SL, Stern N, Palmer D, Tada T, Yeo W, Mo F, Bettinger D, Kirstein MM, Iñarrairaegui M, Gomaa A, Vogel A, Meyer T, Sangro B, Lai P, Kumada T, Johnson PJ. Waked I, et al. Among authors: mo f. Br J Cancer. 2017 Feb 14;116(4):448-454. doi: 10.1038/bjc.2016.423. Epub 2017 Jan 26. Br J Cancer. 2017. PMID: 28125820 Free PMC article.
Phase II study of neoadjuvant carboplatin and paclitaxel followed by radiotherapy and concurrent cisplatin in patients with locoregionally advanced nasopharyngeal carcinoma: therapeutic monitoring with plasma Epstein-Barr virus DNA.
Chan AT, Ma BB, Lo YM, Leung SF, Kwan WH, Hui EP, Mok TS, Kam M, Chan LS, Chiu SK, Yu KH, Cheung KY, Lai K, Lai M, Mo F, Yeo W, King A, Johnson PJ, Teo PM, Zee B. Chan AT, et al. Among authors: mo f. J Clin Oncol. 2004 Aug 1;22(15):3053-60. doi: 10.1200/JCO.2004.05.178. J Clin Oncol. 2004. PMID: 15284255 Clinical Trial.
918 results